Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial - PubMed
4 hours ago
- #randomized trial
- #thrombolysis
- #ischemic stroke
- Standard-dose tenecteplase (0.25 mg/kg) showed higher early substantial reperfusion rates (10.3%) compared to low-dose alteplase (3.6%) in patients with large-vessel occlusion stroke.
- Functional outcomes at 90 days trended better with tenecteplase (common odds ratio 1.47), though not statistically significant, with similar safety profiles including symptomatic intracranial hemorrhage and mortality.
- The study supports tenecteplase as a promising thrombolytic alternative in regions like Japan where low-dose alteplase is standard, particularly prior to mechanical thrombectomy.